ClinicalTrials.gg
CompletedNCT03176459C-SectionUpdated Jan 6, 2021Results posted

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

A Phase 4 interventional study of Exparel + Bupivacaine and Bupivacaine in C-Section and Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 12 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Primary objective: The primary objective of this study is to compare total opioid consumption through 72 hours following EXPAREL+bupivacaine HCl infiltration into the transversus abdominis plane (TAP) after spinal anesthesia to active bupivacaine HCl TAP infiltration after spinal anesthesia in subjects undergoing an elective cesarean section (C-section).

Secondary objective: The secondary objectives are to assess efficacy and safety parameters and patient satisfaction.

Read the detailed description

This is a Phase-4, multicenter, randomized, double-blind, active-controlled study planned in approximately 152 adult subjects undergoing elective C-section. All subjects will remain in the hospital for up to 72 hours postsurgery.

Screening:

Subjects will be screened within 30 days prior to surgery; screening on the day of surgery will be allowed but is discouraged. During the screening visit, subjects will be assessed for any past or present medical conditions that in the opinion of the investigator would preclude them from study participation. After the informed consent form (ICF) is signed, a medical history, surgical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, alcohol breath test and urine drug screen, and clinical laboratory tests (hematology and chemistry) will be performed.

Day of Surgery:

Pre-operative medications: Use of pre-operative analgesics (eg, opioid medications, acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs]) is prohibited.

Eligible subjects will be randomized in a blinded 1:1 ratio to either:

  • Group 1: EXPAREL+bupivacaine TAP infiltration following spinal anesthesia
  • Group 2: Active bupivacaine HCl TAP infiltration following spinal anesthesia On Day 1, prior to the C-section, all subjects will receive a intrathecal injection of 150 mcg preservative-free morphine for spinal injection (eg, Duramorph®) in conjunction with single-shot spinal anesthesia using 1.4-1.6 mL bupivacaine HCl 0.75% and 15 mcg fentanyl. If preservative-free morphine for spinal injection (eg, Duramorph) is unavailable because of a drug shortage, subjects may instead receive an intrathecal injection of 75 mcg preservative-free hydromorphone in conjunction with single-shot spinal anesthesia using 1.4-1.6 mL bupivacaine HCl 0.75% and 15 mcg fentanyl. A combined spinal epidural (CSE) anesthesia technique may also be used provided the epidural component is not used. Subjects who receive the epidural component of the CSE anesthesia must be immediately withdrawn from the study.

Intraoperative medications: The intraoperative use of the following medications is discouraged, but may be permitted if clinically indicated based on the investigator's discretion (all medications must be appropriately recorded [ie, drug, dose, and route of administration]): ketamine and midazolam (Versed®). Prophylactic use of dexamethasone for prevention of nausea and vomiting is prohibited.

After delivery of the baby and prior to the TAP infiltration, a small amount of lidocaine (\<2 mL) may be administered subcutaneously to form a skin wheal over the area of the needle insertion site. A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section. A confirmatory ultrasound picture or video will be taken of each side of the abdomen after the TAP needle position has been established and following infiltration of study drug.

TAP infiltration: Subjects randomized to the EXPAREL+bupivacaine group (Group 1) will receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL, administered as 30 mL (10 mL EXPAREL, 10 mL 0.25% bupivacaine HCl, and 10 mL saline) on each side of the abdomen. Subjects randomized to the active bupivacaine group (Group 2) will receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL, administered as 30 mL (10 mL 0.25% bupivacaine HCl and 20 mL saline) on each side of the abdomen.

Postsurgical Analgesia: Patient-controlled analgesia is not permitted. The following multimodal pain regimen will be initiated immediately following the delivery of the baby:

  • IV ketorolac 15 mg once at the time of skin incision closure and prior to the TAP infiltration
  • Intravenous (IV) acetaminophen 1000 mg at the time of skin incision closure
  • Scheduled oral (PO) acetaminophen 650 mg beginning 6 hours from the administration of the single dose of IV acetaminophen at the end of surgery and then every 6 hours (q6h) for up to 72 hours or hospital discharge
  • Scheduled PO ibuprofen 600 mg beginning 6 hours from the administration of the single dose of IV ketorolac at the end of surgery and then q6h for up to 72 hours or hospital discharge

The date, time, and dose of all standardized multimodal pain medications administered must be recorded. Note: The scheduled PO medication will be administered on a q6h schedule only through hospital discharge.

Rescue Medication: Subjects should only receive opioid rescue pain medication upon request for breakthrough pain. Postsurgical rescue medication will comprise PO immediate-release oxycodone (initiated at 5-10 mg every 4 hours [q4h] or as needed [PRN]). If a subject is unable to tolerate PO medication or fails the PO oxycodone rescue, IV morphine (initiated at 1-2 mg) or hydromorphone (initiated at 0.3-0.5 mg) may be administered q4h or PRN. All surgical and postsurgical opioid and other analgesics (pain medications) administered must be documented through Day 14 postsurgery. Additionally, an unscheduled pain intensity score using a 10-cm visual analog scale (VAS) must be completed immediately prior to any rescue medication while in the hospital.

Permitted medications for the prevention and treatment of possible medication side effects include the following and may be used at the discretion of the study site principal investigator:

  • Ondansetron 4 mg IV immediately after delivery of the baby.
  • Ondansetron 4 mg IV (should not exceed a maximum of 12 mg in a 24-hour period) for intraoperative and postoperative nausea and vomiting
  • Metoclopramide 10 mg PO PRN for nausea and vomiting
  • Nalbuphine IV 2.5 mg PRN for pruritus
  • Naloxone IV 50-100 mcg PRN for pruritus.

Postsurgical Assessments:

Subjects will remain in the hospital for up to 72 hours postsurgery. Postsurgical assessments will include:

  • Opioid use
  • Time of first unassisted ambulation
  • Pain intensity scores using a 10-cm VAS at rest
  • Discharge readiness
  • Subject's satisfaction with postsurgical pain control
  • Overall benefit of anesthesia score (OBAS) questionnaire
  • Quality of recovery 15-item questionnaire (QoR-15)

While in the hospital, subjects will be provided with a Patient Diary and will use the diary to record all scheduled and unscheduled VAS scores. For all scheduled assessments and unscheduled assessments in the hospital, subjects will assess, "How much pain are you experiencing right now" and a vertical mark will be placed on the VAS line to indicate the level of pain experienced at the time of assessment. If a subject is discharged prior to a scheduled VAS assessment, a member of the study site staff will contact the subject to remind her to complete the scheduled VAS assessment at the scheduled time and to record the assessment in the Patient Diary.

At hospital discharge, the subject will be instructed to record in the Patient Diary VAS pain intensity score daily and all pain medications taken following hospital discharge through Day 14.

At home, the subject will assess pain intensity at rest each day at noon (± 4 hours). This assessment should capture her average pain at rest in the prior 24 hours by assessing "What has been your average pain since your last pain assessment?" (ie, from noon on the previous day to the current assessment). At the same time, the subject should record any pain medication (medication name, date, time, and dose) taken in the prior 24 hours.

A phone call will be made to each subject on Day 14 for safety purposes and to inquire as to whether the subject has made any unscheduled phone calls or office visits related to pain; experienced any hospital readmission; or experienced an emergency room visit since hospital discharge. Adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time the ICF is signed through Day 14.

02

Conditions studied

  • C-Section
  • Pain Management

Keywords

  • bupivacaine
  • exparel
  • analgesic
  • TAP Block
03

In context

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females 18 years of age and older at screening.
  2. Term pregnancies of 37 to 42 weeks gestation, scheduled to undergo elective C-section.
  3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.
  4. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who, in the opinion of the study site principal investigator, have a high-risk pregnancy (eg, multiple gestations, pregnancy resulting from in vitro fertilization, gestational diabetes, end-term prolonged bed rest required for medical reasons).
  2. Subjects with a pregnancy-induced medical condition or complication (eg, hypertension, pre-eclampsia, chorioamnionitis).
  3. Subjects with 3 or more prior C-sections.
  4. Pre-pregnancy >50 kg/m2 or otherwise not anatomically appropriate to undergo a TAP block.
  5. Allergy, , intolerance, or to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, NSAIDs, spinal anesthesia).
  6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.
  7. Severely impaired renal or hepatic function (eg, serum creatinine level >2 mg/dL [176.8 μmol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum [AST] level >3 times the [ULN], or serum alanine aminotransferase [ALT] level >3 times the ULN.)
  8. Subjects at an increased risk for bleeding or a coagulation disorder (defined as count less than 80,000 × 103/mm3 or greater than 1.5)
  9. Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the postsurgical period for pain that is not strictly related to the surgery and which may confound the postsurgical assessments.
  10. medical disease in either the mother or baby that, in the opinion of the investigator, would make participation in a clinical study inappropriate. This includes any psychiatric or other disease in the mother that would constitute a contraindication to participation in the study or cause the mother to be unable to comply with the study requirements.
  11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  12. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study
  13. Previous participation in an EXPAREL study. In addition, the subject will be ineligible to receive study drug and will be withdrawn from the study if she meets the following criteria during surgery:
  14. Any clinically significant event or condition uncovered during the surgery (eg, excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postsurgical course.
  15. Receives the epidural component of CSE anesthesia during participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    EXPAREL+bupivacaine TAP infiltration

    Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.

    Drug: Exparel + Bupivacaine

  • Active comparator
    Active bupivacaine TAP infiltration

    Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL

    Drug: Bupivacaine

Interventions

  • DrugExparel + Bupivacaine

    Drug page: Liposomal Bupivacaine

    EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.

  • Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.

06

What researchers measure

Primary outcomes

  1. Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section

    The primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.

    Time frame: 0-72 hours

Secondary outcomes

  1. Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours

    AUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= "no pain" to 30 cm="pain as bad as it could be"). Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, "How much pain are you experiencing right now?" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment. Note higher AUC means more pain over time.

    Time frame: 0-72 hours

  2. Opioid Spared Subjects Through 72 Hours

    Subjects were considered opioid-spared if: * For 0-72 hours opioid consumption, all doses add up to ≤15mg (oral morphine equivalent dose \[OMED\]) * AND the overall benefit of anesthesia score (OBAS) score was 0 for questions 2, 3, 4, 5, and 6. For the OBAS questionnaire, 0 is considered minimal pain and 4 is considered maximum imaginable pain.

    Time frame: 0-72 hours

  3. Total Postsurgical Opioid Consumption Through 24 Hours

    Time frame: 0-24 hours

  4. Total Postsurgical Opioid Consumption Through 48 Hours

    Time frame: 0-48 hours

  5. Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)

    Time frame: 0-168 hours

  6. Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)

    Time frame: 0-336 hours

  7. Time to First Rescue Medication Use

    The time to a subject's first use of an opioid medication for breakthrough pain after the end of surgery

    Time frame: From the end of surgery

  8. Opioid-Free Subjects Through 72 Hours

    Percentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hours

    Time frame: 0-72 hours

07

Results

Posted Jan 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Started9690
Completed9183
Not completed57
Withdrew: Lost to follow-up57

Outcome measures

PrimaryTotal Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section

The primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.

Time frame:
0-72 hours
Reported as:
Least squares mean · MED, mg
Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section
MED, mgEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section15.5 ± 6.6732.0 ± 6.25
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · ANCOVA · p = 0.0117 · Lsm treatment difference: -16.5 · 95% CI -30.8 to -2.2
SecondaryArea Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours

AUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= "no pain" to 30 cm="pain as bad as it could be"). Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, "How much pain are you experiencing right now?" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment. Note higher AUC means more pain over time.

Time frame:
0-72 hours
Reported as:
Least squares mean · cm*hr
Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours
cm*hrEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours147.9 ± 21.13178.5 ± 19.78
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · ANCOVA · p = 0.0020 · Lsm treatment difference (se): -30.6 · 95% CI -75.9 to 14.7
SecondaryOpioid Spared Subjects Through 72 Hours

Subjects were considered opioid-spared if: * For 0-72 hours opioid consumption, all doses add up to ≤15mg (oral morphine equivalent dose \[OMED\]) * AND the overall benefit of anesthesia score (OBAS) score was 0 for questions 2, 3, 4, 5, and 6. For the OBAS questionnaire, 0 is considered minimal pain and 4 is considered maximum imaginable pain.

Time frame:
0-72 hours
Reported as:
Number · percent of participants
Opioid Spared Subjects Through 72 Hours
percent of participantsEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Opioid Spared Subjects Through 72 Hours53.524.7
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine · LSM probability from logistic regression · p = 0.0012 · Odds ratio (or): 3.51 · 95% CI 1.557 to 7.906
SecondaryTotal Postsurgical Opioid Consumption Through 24 Hours
Time frame:
0-24 hours
Reported as:
Least squares mean · MED mg
Total Postsurgical Opioid Consumption Through 24 Hours
MED mgEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Total Postsurgical Opioid Consumption Through 24 Hours2.4 ± 1.825.6 ± 1.70
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · ANCOVA · p = .0543 · Least squares treatment difference: -3.2
SecondaryTotal Postsurgical Opioid Consumption Through 48 Hours
Time frame:
0-48 hours
Reported as:
Least squares mean · MED mg
Total Postsurgical Opioid Consumption Through 48 Hours
MED mgEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Total Postsurgical Opioid Consumption Through 48 Hours9.1 ± 4.4620.5 ± 4.18
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · ANCOVA · p = .0096 · Least squares treatment difference: -11.4
SecondaryTotal Postsurgical Opioid Consumption Through 168 Hours (Day 7)
Time frame:
0-168 hours
Reported as:
Least squares mean · MED mg
Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)
MED mgEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)23.3 ± 9.7545.8 ± 9.13
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · ANCOVA · p = .0175 · Least squares treatment difference: -22.4
SecondaryTotal Postsurgical Opioid Consumption Through 336 Hours (Day 14)
Time frame:
0-336 hours
Reported as:
Least squares mean · MED mg
Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)
MED mgEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)28.2 ± 11.2047.8 ± 10.49
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · ANCOVA · p = .0542 · Least squares treatment difference: -19.6
SecondaryTime to First Rescue Medication Use

The time to a subject's first use of an opioid medication for breakthrough pain after the end of surgery

Time frame:
From the end of surgery
Reported as:
Median · hours
Time to First Rescue Medication Use
hoursEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Time to First Rescue Medication Use53.2 (2.3 to 345.2)41.1 (2.5 to 345.7)
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · Regression, Cox · p = 0.7536
SecondaryOpioid-Free Subjects Through 72 Hours

Percentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hours

Time frame:
0-72 hours
Reported as:
Number · percent of opioid-free participants
Opioid-Free Subjects Through 72 Hours
percent of opioid-free participantsEXPAREL 266mg + Immediate Release (IR) BupivacaineIR Bupivacaine
Opioid-Free Subjects Through 72 Hours51.948.6
Statistical analysis
  • EXPAREL 266mg + Immediate Release (IR) Bupivacaine vs IR Bupivacaine · Regression, Logistic · p = 0.3609 · Odds ratio (or): 1.14

Adverse events

Collected over Screening through postsurgical Day 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL+Bupivacaine TAP Infiltration0/97 (0%)3/97 (3.1%)63/97 (64.9%)
Active Bupivacaine TAP Infiltration0/89 (0%)3/89 (3.4%)50/89 (56.2%)
Most frequent serious events
Most frequent serious events
EventEXPAREL+Bupivacaine TAP InfiltrationActive Bupivacaine TAP Infiltration
Retained placenta or membranesPregnancy, puerperium and perinatal conditions0/971/89
Gestational hypertensionPregnancy, puerperium and perinatal conditions0/971/89
Postpartum hemorrhagePregnancy, puerperium and perinatal conditions0/971/89
Urinary tract infectionRenal and urinary disorders0/971/89
CardiomyopathyCardiac disorders1/970/89
Abdominal wall hematomaGastrointestinal disorders1/970/89
Panic attackPsychiatric disorders1/970/89
Most frequent other events
Most frequent other events
EventEXPAREL+Bupivacaine TAP InfiltrationActive Bupivacaine TAP Infiltration
pruritisSkin and subcutaneous tissue disorders27/9728/89
NauseaGastrointestinal disorders24/9711/89
VomitingGastrointestinal disorders12/976/89
HeadacheNervous system disorders6/9710/89
ConstipationGastrointestinal disorders6/974/89
DizzinessNervous system disorders6/975/89
Back painMusculoskeletal and connective tissue disorders3/975/89
RashSkin and subcutaneous tissue disorders5/973/89

Baseline characteristics

The safety analysis set includes all subjects who receive study drug. All analyses based on the safety set are by actual treatment received.

Age, Continuous
Age, Continuous(years)EXPAREL 266mg + Immediate Release (IR) BupivacaineIR BupivacaineTotal
Mean33.6 ± 5.3733.1 ± 4.4333.4 ± 4.94
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL 266mg + Immediate Release (IR) BupivacaineIR BupivacaineTotal
Female9789186
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EXPAREL 266mg + Immediate Release (IR) BupivacaineIR BupivacaineTotal
Hispanic or Latino121123
Not Hispanic or Latino8478162
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EXPAREL 266mg + Immediate Release (IR) BupivacaineIR BupivacaineTotal
American Indian or Alaska Native000
Asian5510
Native Hawaiian or Other Pacific Islander000
Black or African American131528
White6764131
More than one race134
Unknown or Not Reported11213
Region of Enrollment
Region of Enrollment(participants)EXPAREL 266mg + Immediate Release (IR) BupivacaineIR BupivacaineTotal
United States9789186
American Society of Anesthesiologists classification
American Society of Anesthesiologists classification(Participants)EXPAREL 266mg + Immediate Release (IR) BupivacaineIR BupivacaineTotal
ASA 1112
ASA 29080170
ASA 36814
08

Study locations

12 sites
  • Loma Linda University
    Loma Linda, California 92354, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Henry Ford Health Systems
    Detroit, Michigan 48202, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • St. Peter's University Medical Center
    New Brunswick, New Jersey 08901, United States
  • Columbia Universtiy Medical Center
    New York, New York 10032, United States
  • Duke Regional Hospital
    Durham, North Carolina 27704, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Inova Fairfax Medical Center
    Falls Church, Virginia 22042, United States
  • West Virginia University School of Medicine
    Morgantown, West Virginia 26505, United States
09

References and documents

Publications

  • Nedeljkovic SS, Kett A, Vallejo MC, Horn JL, Carvalho B, Bao X, Cole NM, Renfro L, Gadsden JC, Song J, Yang J, Habib AS. Transversus Abdominis Plane Block With Liposomal Bupivacaine for Pain After Cesarean Delivery in a Multicenter, Randomized, Double-Blind, Controlled Trial. Anesth Analg. 2020 Dec;131(6):1830-1839. doi: 10.1213/ANE.0000000000005075. PubMed 32739962 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Nov 2018, 17 months.

Results were first posted in Jan 2021, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2017
First posted
Jun 5, 2017
StartActual
Jun 1, 2017
Primary completionActual
Nov 20, 2018
CompletionActual
Dec 4, 2018
Results first posted
Jan 6, 2021
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03176459
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Jun 1, 2017
Primary completion
Nov 20, 2018
Completion
Dec 4, 2018
Results posted
Jan 6, 2021
Last update
Jan 6, 2021

Study contacts

Hassan Danesi
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion